1. Elliott P., Andersson B., Arbustini E. et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2008; 29: 270 - 276

2. A Report of the American Collage of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur. Heart J. 2003; 24: P. 1965 - 1991.

3. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011; 25: e 212 - 260.

4. 2014 ESC Guidelines on diagnosis andmanagement of hypertrophic cardiomyopathy. The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. (2014) 35, 2733 - 2779.

5. Elliott P., McKenna W.J. Hypertrophic cardiomyopathy. Lancet 2004; 363: 1881 - 91

6. Габрусенко С.А. Гипертрофическая кардиомиопатия: клинико-инструментальная характеристика, варианты клинического течения, прогноз и особенности медикаментозного лечения. Дисс. докт. мед. наук. Москва, 2009, 309 стр.

7. Elliott P.M, Gimeno J.R, Thaman R. et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92: 785 - 791.

8. Maron B.J., Casey S.A., Hauser R.G., Aeppli D.M. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J. Am. Coll. Cardiol. 2003; 42 (5): 882 - 888.

9. Monserrat L., Elliott P.M., Gimeno J.R. et al. Non-sustained ventricular tachicardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol. 2003; 42 (5): 873 - 879.

10. Elliott P.M., Poloniecki J., Dickie S. et al. Sudden death in hypertrophic cardiomyopathy. Identification of high risk patients. J. Am. Coll. Cardiol. 2000; 36: 2212 - 2218.

11. Spirito P., Autore C., Rapezzi C. et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 2009; 119: 1703 - 1710.

12. Kofflard M.J., Ten Cate F.J., van der LC, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41: 987 - 993.

13. Fananapazir L., Advances in molecular genetics and management of hypertrophic cardiomyopathy. JAMA, 1999; 281 (18): 1746 - 1752.

14. Marian A.J., Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation, 1995; 92 (5): 1336 - 1347.

15. Bos J.M., Towbin J.A., Ackerman M.J. Diagnostic, prognostic and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2009; 54: 201 - 211.

16. Seidman J.G., Seidman C.E. The genetic basis for cardiomyopathy. From mutation identification to mechanismic paradigms. Cell. 2001; 104: 557 - 567.

17. Lopes L.R., Zekavati A., Syrris P. et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med. Genet. 2013; 50: 228 - 239.

18. Olivotto I., Girolami F., Ackerman M.J. et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin. Proc. 2008; 83: 630 - 638.

19. Olivotto I., Girolami F., Sciagra R. et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. J Am. Coll. Cardiol. 2011; 58: 839 - 848.

20. Lopes L.R., Rahman M.S., Elliott P.M. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart 2013; 99: 1800 - 1811.

21. Abchee A., Marian A.J. Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy. J. Investig. Med. 1997; 45 (4): P. 191 - 196.

22. Pasquale F., Syrris P., Kaski J.P. et al. Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. Circ. Cardiovasc. Genet. 2012; 5: 10 - 17.

23. Watkins H., Ashrafian H., Redwood C. Inherited cardiomyopathies. N Engl. J. Med. 2011; 364: 1643 - 1656.

24. Coats C.J., Elliott P.M. Genetic biomarkers in hypertrophic cardiomyopathy. Biomark. Med. 2013; 7: 505 - 516.

25. Scaglia F., Towbin J.A., Craigen W.J. et al. Clinical spectrum, morbidity, and mortality in 113 pediatric patients mitochondrial disease. Pediatrics. 2004; 114: 925 - 931.

26. Monserrat L., Gimeno-Blanes J.R., Marin F. et al. Prevalence of Fabry disease in a hogort of 508 unrelated patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2007; 50: 2399 - 2403.

27. Yang Z., McMahon C.J., Smith L.R. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005; 112: 1612 - 1617.

28. Wilkinson J.D., Lowe A.M., Salbert B.A., Sleeper LA et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am. Heart J. 2012; 164: 442 - 448.

29. Sarkozy A., Digilio M.C, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008; 3: 13.

30. Falk R.H. Diagnosis and management of the cardiac amyloidoses. Circulation 2005; 112: 2047 - 2060.

31. Rapezzi C., Quarta C.C., Obici L. et al. Disease profile anddifferential diagnosis of hereditarytransthyretin-related amyloidosis with exclusively cardiac phenotype: anItalian perspective. Eur. Heart J. 2013; 34: 520 - 528.

32. Sumpter M.D., Tatro L.S., Stoecker W.V., Rader R.K. Evidence for risk of cardiomyopathy with hydroxychloroquine. Lupus 2012; 21: 1594 - 1596.

33. Jarzembowski T.M., John E., Panaro F. et al. Reversal of tacrolimus-related hypertrophic obstructivecardiomyopathy 5 years after kidney transplant in a 6-year-old recipient. Pediatr. Transplant. 2005; 9: 117 - 121.

34. Maron M.S., Olivotto I., Betocchi S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 2003; 348: 295 - 303.

35. Sherrid M.V., Gunsburg D.Z., Moldenhauer S. et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol, 2000; 36: 1344 - 1354.

36. Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002; 287: 1308 - 1320.

37. Чигинева В.В., Мазур Н.А. Нарушения диастолической функции левого желудочка при гипертрофической кардиомиопатии. В кн. "Диастолическая дисфункция миокарда". Москва, 2001: стр. 54 - 66.

38. Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyohathy. Lancet, 2000; 355: 58 - 60.

39. Matsumura Y., Elliot P., Virdee M. et al. Left ventricular diastolic function assessed using Doppler tissue imaging in patients with hypertrophic cardiomyopathy: relation to symptoms and exercise capacity. Heart, 2002; 87: 247 - 251.

40. Maron M.S., Olivotto I., Maron B.J. et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2009; 54: 866 - 875.

41. Cecchi F., Olivotto I., Gistri R. et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N. Engl. J. Med 2003; 349: 1027 - 1035.

42. Spirito P., Seidman C.E., McKenna W. et al. The management of hypertrophic cardiomyopathy. N. Engl. J. Med., 1997; 336: 775 - 785.

43. Пирцхалаишвили Н.А. Внутисердечная гемодинамика и состояние коронарного кровотока у больных гипертрофической кардиомиопатией: Дис. канд. мед. наук, М. - 1992. - 150 с.

44. Montalescot G., Sechtem U, Achenbach S. et al. 2013 ESC guidelineson the management of stable coronary artery disease: the Task Force on the management ofstable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34: 2949 - 3003.

45. Maron B.J. Hypertrophic cardiomyopathy: an important global disease. Am. J. Med. 2004; 116: 63 - 65.

46. Zou Y., Song L., Wang Z. et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am. J. Med. 2004; 116: 14 - 18.

47. Maron B.J., Gardin J.M., Flack J.M. et al. Prevalence of hyhertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995; 92: 785 - 789.

48. Maron BJ, Spirito P, Roman MJ, Paranicas M, Okin PM, Best LG, Lee ET, Devereux RB. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am. J. Cardiol. 2004; 93: 1510 - 1514.

49. Lipshultz S.E., Sleeper L.A., Towbin J.A. et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N. Engl. J. Med. 2003; 348: 1647 - 1655.

50. Nugent A.W., Daubeney P.E., Chondros P. et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005; 112: 1332 - 1338.

51. Ng C.T., Chee T.S., LingL. F. et al. Prevalence of hypertrophic cardiomyopathy on an electrocardiogram-based pre-participation screening programme in a young male South-East Asian population: results from the Singapore Armed Forces Electrocardiogram and Echocardiogram screening protocol. Europace 2011; 13: 883 - 888.

52. Wigle E.D., Rakowsky H., Kimball B.P., Williams W.G. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995; 92: P. 1680 - 1692.

53. Габрусенко С.А., Сафрыгина Ю.В., Наумов В.Г. Трудности первичной диагностики гипертрофической кардиомиопатии (результаты ретроспективного анализа). 4-я международная научная конференция "Лечение кардиомиопатий и заболеваний миокарда". Москва, 2005, (сборник материалов), стр. 20.

54. Rapezzi C., Arbustini E., Caforio A.L. et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 1448 - 1458.

55. Geske J.B., McKie P.M., Ommen S.R., Sorajja P. B-type natriureticpeptide and survivalin hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2013; 61: 2456 - 2460.

56. Coats C.J., Gallagher M.J., Foley M. et al. Relation between serumN-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur. Heart J. 2013; 34: 2529 - 2537.

57. Сафрыгина Ю.В. Клиническое значение определения содержания натрийуретических пептидов в крови у больных гипертрофической кардиомиопатией при проспективном наблюдении: Дисс. ... канд. мед. наук, М. - 2008. - 118 с.

58. Brito D., Miltenberger-Miltenyi G., Vale P.S. et al. Sarcomerichypertrophic cardiomyopathy: genetic profile in a Portuguese population. Rev. Port Cardiol. 2012; 31: 577 - 587.

59. Morita H., Rehm H.L., Menesses A. et al. Shared genetic causes of cardiac hypertrophyin children and adults. N. Eng. J. Med. 2008; 358: 1899 - 1908.

60. Lopes L.R., Zekavati A., Syrris P. et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 2013; 50: 228 - 239.

61. Godard B., Raeburn S., Pembrey M. et al. Genetic informationand testing in insurance and employment: technical, social and ethicalissues. Eur. J. Hum. Genet. 2003; 11 Suppl 2: S123 - S142.

62. Cassiman JJ. Research network: EuroGentest: a European Networkof Excellenceaimed at harmonizing genetic testing services. Eur. J. Hum. Genet. 2005; 13: 1103 - 1105.

63. American Society of Human Genetics Board of Directors ACoMGBoD. Points toconsider: ethical, legal, and psychosocial implications of genetic testing in childrenand adolescents. Am. J. Hum. Genet. 1995; 57: 1233 - 1241.

64. Olivotto I., Girolami F., Ackerman M.J. et al. Myofilamentprotein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008; 83: 630 - 638.

65. Fokstuen S., Munoz A., Melacini P. et al. Rapid detection of genetic variants in hypertrophic cardiomyopathy bycustomDNAresequencing array in clinical practice. J. Med. Genet. 2011; 48: 572 - 576.

66. Christiaans I., Birnie E., Bonsel G.J. et al. Manifest disease, risk factors for sudden cardiac death, and cardiacevents in a large nationwide cohort of predictively tested hypertrophic cardiomyopathymutation carriers: determining the best cardiological screening strategy. Eur. Heart J. 2011; 32: 1161 - 1170.

67. Andersen P.S., Havndrup O., Hougs L. et al. Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encodinggenes in Danish hypertrophic cardiomyopathy patients and relatives. Hum. Mutat. 2009; 30: 363 - 370.

68. Havndrup O., Bundgaard H., Andersen P.S. et al. Outcome of clinical versus genetic family screening in hypertrophiccardiomyopathy with focus on cardiac beta-myosin gene mutations. Cardiovasc. Res. 2003; 57: 347 - 357.

69. Charron P., Arad M., Arbustini E. et al. Genetic counselling andtesting in cardiomyopathies: a position statement of the European Society of Cardiology Working Group onMyocardial and Pericardial Diseases. Eur. Heart J. 2010; 31: 2715 - 2726.

70. Richard P., Charron P., Carrier L. et al. Hypertrophic cardiomyopathy: distribution of diseasegenes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003; 107: 2227 - 2232.

71. Ingles J., McGaughran J., Scuffham P.A. et al. A cost-effectivenessmodel of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart 2012; 98: 625 - 630.

72. Jensen M.K, Havndrup O., Christiansen M. et al. Penetrance of hypertrophic cardiomyopathy inchildren and adolescents: a 12-year follow-up study of clinical screening and predictivegenetic testing. Circulation 2013; 127: 48 - 54.

73. Basso C., Burke M., Fornes P. et al. Guidelines for autopsyinvestigation of sudden cardiac death. Pathologica 2010; 102: 391 - 404.

74. Pelliccia A., Corrado D., Bjornstad H.H. et al. Recommendations for participationin competitive sport and leisure-time physical activity in individuals with cardiomyopathies, myocarditis and pericarditis. Eur J Cardiovasc Prev Rehabil 2006; 13: 876 - 885.

75. Borry P., Stultiens L., Nys H. et al. Presymptomatic and predictivegenetic testing in minors: a systematic reviewof guidelines and position papers. Clin. Genet 2006; 70: 374 - 381.

76. Ross L.F., Saal H.M. David K.L., Anderson R.R. Technical report: Ethical and policyissues in genetic testing and screening of children. Genet. Med. 2013; 15: 234 - 245.

77. McLeod C.J., Ackerman M.J., Nishimura R.A. et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J. Am. Coll. Cardiol. 2009; 54: 229 - 233.

78. Rapezzi C., Arbustini E., Caforio A.L. et al. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESCWorking Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013; 34: 1448 - 1458.

79. Charron P., Forissier J.F., Amara M.E. et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int. J. Cardiol. 2003; 90: 33 - 38.

80. Adabag A.S., Casey S.A., Kuskowski M.A., Maron BJ. Spectrumand prognostic significance of arrhythmias on ambulatory Holter electrocardiogram inhypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2005; 45: 697 - 704.

81. O'Mahony C., Jichi F., Pavlou M. et al. A novel clinical riskprediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur. Heart J. 2014; 35: 2010 - 2020.

82. Moya A., Sutton R., Ammirati F. et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur. Heart J. 2009; 30: 2631 - 2671.

83. Brignole M., Vardas P., Hoffman E. et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace 2009; 11: 671 - 687.

84. Klues H.G., Schiffers A., Maron B.J. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J. Am. Coll. Cardiol. 1995; 26: 1699 - 1708.

85. Cerqueira M.D., Weissman N.J., Dilsizian V. et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002; 105: 539 - 542.

86. Senior R., Becher H., Monaghan M. et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr 2009; 10: 194 - 212.

87. Klues H.G., Proschan M.A., Dollar A.L. et al. Echocardiographic assessment of mitral valve size in obstructive hypertrophic cardiomyopathy. Anatomic validation from mitral valve specimen. Circulation 1993; 88: 548 - 555.

88. Harrigan C.J., Appelbaum E., Maron B.J. et al. Significance of papillary muscle abnormalities identified by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am. J. Cardiol. 2008; 101: 668 - 673.

89. Wigle E.D. Cardiomyopathy: The diagnosis of hypertrophic cardiomyopathy. Heart 2001; 86: 709 - 714.

90. Sherrid M.V., Wever-Pinzon O., Shah A., Chaudhry F.A. Reflections of inflections in hypertrophic cardiomyopathy. J. Am. Col. Cardiol. 2009; 54: 212 - 219.

91. Dimitrow P.P., Bober M., Michalowska J., Sorysz D. Left ventricular outflow tract gradient provoked by upright position orexercise in treated patients with hypertrophic cardiomyopathy without obstruction at rest. Echocardiography 2009; 26: 513 - 520.

92. Hess O.M. Risk stratification in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2003; 42 (5): 880 - 881.

93. Nagueh S.F., Appleton C.P., Gillebert T.C. et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur. J. Echocardiogr. 2009; 10: 165 - 193.

94. Maron M.S., Olivotto I., Betocchi S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 2003; 348: 295 - 303.

95. Elliott P., Gimeno J., Tome M., McKenna W. Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur. Heart J. 2006; 27: 3073 - 3074.

96. Spirito P., Bellone P., Harris K.M. et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 2000; 342: 1778 - 1785.

97. Losi M.A., Nistri S., Galderisi M. et al. Echocardiography in patients with hypertrophic cardiomyopathy: usefulness of old and new techniques in the diagnosis and pathophysiological assessment. Cardiovasc Ultrasound 2010; 8: 7.

98. Kubo T., Gimeno J.R., Bahl A. et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J. Am. Coll. Cardiol. 2007; 49: 2419 - 2426.

99. Biagini E., Spirito P., Rocchi G. et al. Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am. J. Cardiol. 2009; 104: 1727 - 1731.

100. Maron M.S., Olivotto I., Zenovich A.G. et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114: 2232 - 2239.

101. Shah J.S., Esteban M.T., Thaman R. et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008; 94: 1288 - 1294.

102. Losi M.A., Betocchi S., Barbati G. et al. Prognostic significance of left atrial volume dilatation in patients with hypertrophic cardiomyopathy. J. Am. Soc. Echocardiogr. 2009; 22: 76 - 81.

103. Nistri S., Olivotto I., Betocchi S. et al. Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy). Am. J. Cardiol. 2006; 98: 960 - 965.

104. Senior R., Becher H., Monaghan M. et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur. J. Echocardiogr. 2009; 10: 194 - 212.

105. Yu E.H., Omran A.S., Wigle E.D. et al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J. Am. Coll. Cardiol. 2000; 36: 2219 - 2225.

106. Flachskampf F.A., Badano L., Daniel W.G. et al. Recommendations for transoesophageal echocardiography: update 2010. Eur. J. Echocardiogr. 2010; 11: 557 - 576.

107. Kim M.S., Klein A.J., Groves B.M. et al. Left ventricular outflow tract obstruction inthe presence of asymmetric septal hypertrophy and accessory mitral valvetissue treated with alcohol septal ablation. Eur. J. Echocardiog. 2008; 9: 720 - 724.

108. O'Hanlon R., Assomull R.G., Prasad S.K. Use of cardiovascular magnetic resonance for diagnosis and management in hypertrophic cardiomyopathy. Curr. Cardiol. Rep. 2007; 9: 51 - 56.

109. Burton H., Alberg C., Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services - A Needs Assessment and Service Review. PHG Fundation, UK, 2009.

110. Rudolph A., Abdel-Aty H., Bohl S. et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009; 53: 284 - 291.

111. Green J.J., Berger J.S., Kramer C.M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012; 5: 370 - 377.

112. O'Hanlon R., Grasso A., Roughton M. et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2010; 56: 867 - 874.

113. Sado D.M., White S.K., Piechnik S.K. et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ. Cardiovasc. Imaging 2013; 6: 392 - 398.

114. Vogelsberg H., Mahrholdt H., Deluigi C.C. et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J. Am. Coll. Cardiol. 2008; 51: 1022 - 1030.

115. Rickers C., Wilke N.M., Jerosch-Herold M. et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112: 855 - 861.

116. Moon J.C., Fisher N.G., McKenna W.J., Pennell D.J. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with nondiagnostic echocardiography. Heart 2004; 90: 645 - 649.

117. Weinsaft J.W., Kim H.W., Crowley A.L. et al. LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR. JACC Cardiovasc Imaging 2011; 4: 702 - 712.

118. Prinz C., Schwarz M., Ilic I. et al. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy. Can. J. Cardiol. 2013; 29: 358 - 363.

119. Maron M.S., Finley J.J., Bos J.M. et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008; 118: 1541 - 1549.

120. Syed I.S., Glockner J.F., Feng D. et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010; 3: 155 - 164.

121. Kwon D.H., Smedira N.G., Rodriguez E.R. et al. Cardiacmagnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J. Am. Coll. Cardiol. 2009; 54: 242 - 249.

122. Schroeder S., Achenbach S., Bengel F. et al. Cardiac computed tomography: indications, applications, limitations, and training requirements: report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur. Heart J. 2008; 29: 531 - 556.

123. Rapezzi C., Quarta C.C., Guidalotti P.L. et al. Role of (99m) Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretinrelated cardiac amyloidosis. JACC Cardiovasc Imaging 2011; 4: 659 - 670.

124. Romero-Farina G., Candell-Riera J., Galve E. et al Do myocardial perfusion SPECT and radionuclide angiography studies in adult patients with hypertrophic cardiomyopathy have prognostic implications? J. Nucl. Cardiol. 2004; 11: 578 - 586.

125. Soler R., Rodriguez E., Monserrat L. et al. Magnetic resonance imaging of delayed enhancement in hypertrophic cardiomyopathy: relationship with left ventricular perfusion and contractile function. J. Comput. Assist. Tomogr. 2006; 30: 412 - 420.

126. Barbosa C.A., Castro C.C., Avila L.F. et al. Late enhancement and myocardial perfusion in hypertrophic cardiomyopathy (comparison between groups). Arq. Bras. Cardiol. 2009; 93: 426 - 25.

127. Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013; 34: 2949 - 3003.

128. Zipes D.P., Camm A.J., Borggrefe M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8: 746 - 837.

129. Okayama S., Uemura S., Soeda T. et al. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardialablation for hypertrophic obstructive cardiomyopathy. J. Cardiovasc Comput. Tomogr. 2010; 4: 62 - 65.

130. Leone O., Veinot J.P., Angelini A. et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc. Pathol. 2012; 21: 245 - 274.

131. Maki S., Ikeda H., Muro A. et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. Am. J. Cardiol. 1998; 82: 774 - 778.

132. Gimeno J.R., Tome-Esteban M., Lofiego C. et al. Exercise-induced ventricular arrhythmias and risk ofsudden cardiac death in patients with hypertrophic cardiomyopathy. Eur. Heart J. 2009; 30: 2599 - 2605.

133. Dimitrow P.P., Chojnowska L., Rudzinski T. et al Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in anewmodel of maximalized follow-up. Eur. Heart J. 2010; 31: 3084 - 3093.

134. Spirito P., Bellone P., Harris K.M. et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 2000; 342: 1778 - 1785.

135. Williams L., Frenneaux M. Syncope in hypertrophic cardiomyopathy: mechanismsand consequences for treatment. Europace 2007; 9: 817 - 822.

136. Elliott P.M., Gimeno B. Jr., Mahon N.G. et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001; 357: 420 - 424.

137. Sadoul N., Prasad K., Elliott P.M. et al. Prospectiveprognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997; 96: 2987 - 2991.

138. Maron B.J., Shen W.-K., Link M.S. et al. Efficacy of implantable cardioverter-defibrillator for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 2000; 342: 365 - 373.

139. Maron B.J., Spirito P., Shen W.K. et al. Implantable cardioverter-defibrillator and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA, 2007; 298: 405 - 412.

140. Spoladore R., Maron M.S., D'Amato R. et al. Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. Eur. Heart J. 2012; 33: 1724 - 1733.

141. Sherrid M.V., Gunsburg D.Z., Sharma S. Medical treatment of hypertrophic cardiomyopathy. Curr. Cardiol. Rep. 2000; 2 (2): 148 - 153.

142. Wigle E.D., Rakowsky H., Kimball B.P., Williams W.G. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995; 92: 1680 - 1692.

143. Roberts R., Sigwart U. Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy. Circulation. 2005; 12 (July): 293 - 296.

144. Ostman-Smith I., Wettrell G., Riesenfeld T. A cohort study of chaldhood hypertrophic cardiomyopathy. Improved survival following high-dose beta-adrenoceptor antagonist treatment. J. Am. Coll. Cardiol. 1999; 34: 1813 - 1822.

145. Stenson R.E., Flamm M.D. Jr., Harrison D.C., Hancock E.W. Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. Am. J. Cardiol. 1973; 31: 763 - 773.

146. Tendera M., Wycisk A., Schneeweiss A. et al. Effect of sotalol onarrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. Cardiology 1993; 82: 335 - 342.

147. Bonow R.O., Dilsizian V., Rosing D.R. et al. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy. Short- and long-term effects. Circulation. 1985; 72: 853 - 864.

148. Gistri R., Cecchi F., Choudhury L. et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am. J. Cardiol. 1994; 74: 363 - 368.

149. Epstein S.E., Rosing D.R. Verapamil: its potential for causing serious complication in patients with hypertrophic cardiomyopathy. Circulation. 1981; 64: 437 - 441.

150. Gilligan D.M., Chan W.L., Joshi J. et al. A double-blind, placebo-controlled crossover trial of nodalol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 1993; 21: 1672 - 1679.

151. Sherrid M.V., Barac I., McKenna W.J. et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2005; 45: 1251 - 1258.

152. Sherrid MV., Shetty A., Winson G. et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. Circ Heart Fail 2013; 6: 694 - 702.

153. Hamada M., Shigematsu Y., Inaba S. et al. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction. Circ. J., 2005; 69 (8): 940 - 945.

154. McKenna W.J., Oakley C.M., Krikler D.M., Goodwin J.F. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br. Heart J., 1985; 53; 412 - 416.

155. Betocchi S., Piscione F., Losi M.A. et al Effects of diltiazem onleft ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am. J. Cardiol., 1996; 78: 451 - 457.

156. Toshima H., Koga Y., Nagata H. et al. Comparable effects of oral diltiazem and verapamil in the tratment of hypertrophic cardiomyopathy. Double-blindcrossoverstudy. Jpn. Heart J. 1986; 27: 701 - 715.

157. Olivotto I., Cecchi F., Casey S.A. et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation, 2001; 104: 2517 - 2524.

158. Maron B.J., Olivotto I., Bellone P. et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol., 2002; 39: 301 - 307.

159. Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrialfibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012; 33: 2719 - 2747.

160. Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for themanagement of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360 - 1420.

161. Robinson K., Frenneaux M.P., Stockins B. et al. Atrial fibrillation in hypertrophic cardiomyopathy. A longitudinal study. J. Am. Coll. Cardiol., 1990; 15: 1279 - 1285.

162. Di Donna P., Olivotto I., Delcre S.D. et al. Efficacy of catheter ablation for atrialfibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 2010; 12: 347 - 355.

163. Bunch T.J., Munger T.M., Friedman P.A. et al. Substrateand procedural predictors of outcomes after catheter ablation for atrial fibrillationin patients with hypertrophic cardiomyopathy. J. Cardiovasc. Electrophysiol. 2008; 19: 1009 - 1014.

164. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Eng.1 J. Med. 2009; 360: 2066 - 2078.

165. McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC Guidelinesfor the diagnosis and treatment of acute and chronic heartfailure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developedin collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2012; 33: 1787 - 1847.

166. Menon S.C., Ackerman M.J., Ommen S.R. et al. Impact of septal myectomy on left atrial volume and left ventricular diastolic filling patterns: an echocardiographic study of young patients with obstructive hypertrophic cardiomyopathy. J. Am. Soc. Echocardiogr. 2008; 21: 684 - 688.

167. Burton H., Alberg C., Stewart A. Heart to Heart: Inherited Cardiovascular Conditions Services - A Needs Assessment and Service Review. PHG Fundation, UK, 2009.

168. Agarwal S., Tuzcu E.M., Desai M.Y. et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2010; 55: 823 - 834.

169. Alam M., Dokainish H., Lakkis N.M. Hypertrophic obstructive cardiomyopathyalcohol septal ablation vs. myectomy: a meta-analysis. Eur. Heart J. 2009; 30: 1080 - 1087.

170. Leonardi R.A., Kransdorf E.P., Simel D.L., Wang A. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ. Cardiovasc. Interv. 2010; 3: 97 - 104.

171. Kaple R.K., Murphy R.T., DiPaola L.M. et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann. Thorac. Surg 2008; 85: 1527 - 1535.

172. Orme N.M., Sorajja P., Dearani J.A. et al. Comparison of surgical septal myectomy to medical therapy alone in patients with hypertrophic cardiomyopathy and syncope. Am. J. Cardiol. 2013; 111: 388 - 392.

173. Schoendube F.A., Klues H.G., Reith S. et al. Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995; 92: II122 - II127.

174. Maron B.J., Ommen S.R., Nishimura R.A. et al. Myths about surgical myectomy: rumors of its death have been greatly exaggerated. Am. J. Cardiol., 2008; 101: 887 - 889.

175. Smedira N.G., Lytle B.W., Lever H.M. et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann. Thorac. Surg. 2008; 85: 127 - 133.

176. Seiler С., Hess O.M., Schoenbeck M. et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J. Am. Coll. Cardiol. 1991; 17: 634 - 642.

177. Ommen S.R., Maron B.J., Olivotto I. et al. Long-term Effects of septal Myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. 2005; 46 (3): 15 - 22.

178. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet, 1995; 346: 211 - 214.

179. Gietzen F.H., Leuner C.J., Raute-Kreinsen U. et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur. Heart J. 1999; 20: 1342 - 1354.

180. Masur W., Nagueh S.F., Lakkis N.M. et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation, 2001; 103: 1492 - 1496.

181. van Dockum W.G., Beek A.M., Ten Cate F.J. et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation, 2005; 111: 2503 - 2508.

182. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy. Curr. Cardiol. Rep., 2001; 3: 160 - 166.

183. Fernandes V.L., Nielsen C., Nagueh S.F. et al. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: the Baylor and Medical University of South Carolina experience 1996 to 2007. JACC Cardivasc. Interv. 2008; 1: 561 - 570.

184. Serber E.R., Sears S.F., Nielsen C.D. et al. Depression, anxiety and quality of life in patients with obstructive hypertrophic cardiomyopathy three months after alcohol septal ablation. Am. J. Cardiol., 2007; 100: 1592 - 1597.

185. Leonardi R.A., Kransdorf E.P., Simel D.L. et al. Meta-analyses of septal reduction therapies for obstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ. Cardiovasc. Interv., 2010; 3: 97 - 104.

186. Kwon D.H., Kapadia S.R., Tuzcu E.M. et al. Long-term outcomes to high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JACC Cardiovasc. Interv., 2008; 1: 432 - 438.

187. Sorajja P., Valeti U., Nishimura R.A. et al. Outcome of alcohol septal ablation. for obstructive hypertrophic cardiomyopathy. Circulation 2008; 118: 131 - 139.

188. Alam M., Dokainish H., Lakkis N.M. et al. Hypertrophic obstructive cardiomyopathy - alcohol septal ablation vs myectomy: a meta-analysis. Eur. Heart J., 2009; 30: 1080 - 1087.

189. Olivotto I., Ommen S.R., Maron M.S. et al. Surgacal myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: will there ever be a randomized trial? J. Am. Coll. Cardiol., 2007; 50: 831 - 834.

190. Ten Cate F.J., Soliman O.I., Michels M. et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ. Heart Fail., 2010; 3: 362 - 369.

191. Jeanreanauld X., Aebischer N., Koppenberger L. Influence of DDD pacing on LV parameters in hypertrophic obstructive cardiomyopathy: Result of the PIC Study. JACC, 1998; 31: 183.

192. Maron B.J., Nishimura R.A., McKenna W.J. et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999; 99: 2927 - 2933.

193. Nishimura R.A., Trusty J.M., Hayes D.L. et al. Dual-chamber pacing for hypertrophic cardiomyopathy. A randomized, double-blind, crossover trial. J. Am. Coll. Cardiol. 1997; 29: 435 - 441.

194. Slade A.K., Sadoul N., Shapiro L. et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart 1996; 75: 44 - 49.

195. Mickelsen S., Bathina M., Hsu P. et al. Doppler evaluation of thedescending aorta in patients with hypertrophic cardiomyopathy: potential forassessing the functional significance of outflow tract gradients and for optimizingpacemaker function. J. Interv. Card. Electrophysiol. 2004; 11: 47 - 53.

196. Gao Y.C., Li Y., Han Z.H. et al. Transcoronary ablation ofseptal hypertrophy versus dual-chamber cardiac pacing for the treatment ofaged patients with hypertrophic obstructive cardiomyopathy]. Zhonghua Xin XueGuan Bing Za Zhi 2007; 35: 333 - 336.

197. Sherrid M.V., Shetty A., Winson G. et al. Treatment of obstructive hypertrophic cardiomyopathy symptomsand gradient resistant to first-line therapy with beta-blockade or verapamil. Circ. Heart Fail. 2013; 6: 694 - 702.

198. O'Mahony C., Lambiase P.D., Quarta G. et al. The long-term survivaland the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart 2012; 98: 116 - 125.

199. Maron B.J., Spirito P., Shen W.K. et al. Implantable cardioverter-defibrillators and revention ofsudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405 - 412.

200. Syska P., Przybylski A., Chojnowska L. et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 2010; 21: 883 - 889.

201. Schinkel A.F., Vriesendorp P.A., Sijbrands E.J. et al. Outcome and complications after implantable cardioverter defibrillator therapyin hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ. Heart Fail. 2012; 5: 552 - 559.

202. Lin G., Nishimura B.A., Gersh B.J. et al. Device complications and inappropriate implantable cardioverter-defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009; 95: 709 - 714.

203. Braunschweig F., Boriani G., Bauer A. et al. Management of patients receivingimplantable cardiac defibrillator shocks: recommendations for acute and long-termpatient management. Europace 2010; 12: 1673 - 1690.

204. Maron B.J., Spirito P., Ackerman M.J. et al. Prevention ofsudden cardiac death with implantable cardioverter-defibrillators in children andadolescents with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2013; 61: 1527 - 1535.

205. Kaski J.P., Tome Esteban M.T., Lowe M. et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 2007; 93: 372 - 374.

206. Kato T.S., Takayama H., Yoshizawa S. et al. Cardiac transplantation in patients with hypertrophic cardiomyopathy. Am. J. Cardiol. 2012; 110: 568 - 574.

207. Biagini E., Spirito P., Leone O. et al. Heart transplantation in hypertrophic cardiomyopathy. Am. J. Cardio.1 2008; 101: 387 - 392.

208. Coutu M., Perrault L.P., White M. et al. Cardiac transplantation for hypertrophic cardiomyopathy: a valid therapeuticoption. J. Heart Lung Transplant. 2004; 23: 413 - 417.

209. Maron M.S., Kalsmith B.M., Udelson J.E. et al. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ. Heart Fai. 2010; 3: 574 - 579.

210. Melacini P., Basso C., Angelini A. et al. Clinicopathological ESC Guidelines 2779 by guest on October 3, 2016 http://eur heart j.oxfordjournals.org/Downloaded from profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur. Heart J. 2010; 31: 2111 - 2123.

211. Olivotto I., Cecchi F., Poggesi C. et al. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ. Heart Fai.1 2012; 5: 535 - 546.

212. McLeod C.J., Ackerman M.J., Nishimura R.A. et al. Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram. J. Am. Col.1 Cardiol. 2009; 54: 229 - 233.

213. Olivotto I., Montereggi A., Mazzuoli F., Cecchi F. Clinical utility and safety of exercise testing in patient swith hypertrophiccardiomyopathy. G. Ital. Cardiol. 1999; 29: 11 - 19.

214. Todiere G., Aquaro G.D., Piaggi P. et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2012; 60: 922 - 929.